Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX Code: PBT) covers the month of November 2013. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act 2001 (Cth) regarding a specific share issuance.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to a specific capital event:
- Shares Issued: 143,700 Ordinary Fully Paid Shares
- Issue Date: November 5, 2013
- Total Issue Price: AUD$69,028
Material Changes
The material change reported is the issuance of 143,700 ordinary shares without disclosure to investors under Part 6D.2 of the Corporations Act. The company confirms compliance with Chapter 2M and Section 674 of the Corporations Act as of the filing date.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. Regarding risks and contingencies, the company explicitly states that as of the notice date, there is no "excluded information" required to be disclosed under subsection 708A(7) of the Corporations Act.
Investor Verification Checklist
- Verify the total number of shares issued (143,700) and the aggregate consideration received (AUD$69,028).
- Confirm the company's compliance status with Chapter 2M and Section 674 of the Corporations Act.
- Note that this filing does not contain operational or financial performance data for the period.